Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
11.45% $1.382
America/New_York / 27 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 22.07 mill |
EPS: | -1.500 |
P/E: | -0.920 |
Earnings Date: | May 08, 2024 |
SharesOutstanding: | 15.97 mill |
Avg Daily Volume: | 0.0454 mill |
RATING 2024-03-27 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Sell | |
P/E: | Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | |||||
Ebit | ||||||
Asset | ||||||
Debt | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.920 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.16x |
Company: PE -0.920 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.905 (-34.51%) $-0.477 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 1.277 - 1.483 ( +/- 7.46%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-21 | Minai-azary Jennifer Lynn | Buy | 160 115 | Stock Option (right to buy) |
2024-03-21 | Levit Alex C. | Buy | 153 515 | Stock Option (right to buy) |
2024-03-21 | Lehr Martin A. | Buy | 291 402 | Stock Option (right to buy) |
2023-05-31 | Kantoff Philip W. | Buy | 25 000 | Stock Option (right to buy) |
2023-05-31 | West Linda | Buy | 25 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
100.00 |
Last 72 transactions |
Buy: 4 162 098 | Sell: 2 098 089 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $1.382 (11.45% ) |
Volume | 0.216 mill |
Avg. Vol. | 0.0454 mill |
% of Avg. Vol | 475.27 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.